Clinical Study

Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II Study

V. Surmont,1 J. G. J. V. Aerts,1,2 K. Y. Tan,3 F. Schramel,4 R. Vernhout,5 H. C. Hoogsteden,1 and R. J. van Klaveren1

1 Department of Pulmonology, Erasmus MC-Daniel Den Hoed Cancer Center, Rotterdam, The Netherlands
2 Department of Pulmonology, Amphia Hospital, Breda, The Netherlands
3 Department of Pulmonology, St. Franciscus Gasthuis, Rotterdam, The Netherlands
4 Department of Pulmonology, St. Antonius, Nieuwegein, The Netherlands
5 Department of Trials and Statistics, Erasmus MC-Daniel Den Hoed Cancer Center, Rotterdam, The Netherlands

Correspondence should be addressed to V. Surmont, veerle.surmont@ugent.be

Received 17 April 2009; Revised 17 July 2009; Accepted 19 August 2009

Recommended by James L. Mulshine

Background. sequential chemotherapy can maintain dose intensity and preclude cumulative toxicity by increasing drug diversity. Purpose. to investigate the toxicity and efficacy of the sequential regimen of gemcitabine followed by paclitaxel in first line advanced stage non-small cell lung cancer (NSCLC) patients with good performance status (PS). Patients and methods. gemcitabine 1250 mg/m² was administered on day 1 and 8 of course 1 and 2; Paclitaxel 150 mg/m² on day 1 and 8 of course 3 and 4. Primary endpoint was response rate (RR), secondary endpoints toxicity and time to progression (TTP). Results. Of the 21 patients (median age 56, range 38–80 years; 62% males, 38% females) 10% (2/21) had stage IIIB, 90% (19/21) stage IV, 15% PS 0, 85% PS 1. 20% of patients had a partial response, 30% stable disease, 50% progressive disease. Median TTP was 12 weeks (range 6–52 weeks), median overall survival (OS) 8 months (range 1–27 months), 1-year survival was 33%. One patient had grade 3 hematological toxicity, 2 patients a grade 3 peripheral neuropathy.

Conclusions. sequential administration of gemcitabine followed by paclitaxel in first line treatment of advanced NSCLC had a favourable toxicity profile, a median TTP and OS comparable with other sequential trials and might, therefore, be a treatment option for NSCLC patients with high ERCC1 expression.

Copyright © 2009 V. Surmont et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Even with the use of novel chemotherapeutic agents, the prognosis of patients with advanced NSCLC remains poor. Platinum-based chemotherapy combined with either gemcitabine, vinorelbine, paclitaxel, or docetaxel is currently the mainstay in the treatment of advanced NSCLC[1–5]. Standard therapy for advanced NSCLC results in response rates of 20% to 40%, a median survival between 8–10 months, and 1-year survival rates between 30% and 50% [1–3].

Chemotherapy may lead to the selection of chemoresistant tumor clones. Frequent exposure to different cytotoxic agents with brief intervals may inhibit tumor regrowth and limit the emergence of drug resistant cell lines [6, 7]. Sequential chemotherapy administration offers the possibility to increase drug diversity while maintaining dose intensity, potentially leading to less dose reductions, an optimal dose intensity, and prolonged treatment duration and disease control [6, 7].

In order to investigate the validity of this approach, we decided to conduct a nonrandomized phase II study, to investigate the toxicity and efficacy in terms of time to progression and response rate of a sequential single agent regimen consisting of gemcitabine followed by paclitaxel in the first-line treatment of patients with stage IIIB/IV NSCLC.
2. Patients and Methods

In this multicenter trial patients with stage IIIB (malignant pleural effusion or N3 due to supraclavicular lymph node involvement) and stage IV have been enrolled between 2003 and 2006. The study was approved by the ethical committees of the Erasmus MC and 4 other hospitals. Patients were included after written informed consent. Other selection criteria were measurable disease according to the RECIST criteria [8], age over 18 years, WHO performance status less than 2, adequate bone marrow reserve (absolute neutrophil count ≥ 2.0 × 10^9/L, platelet count ≥ 100 × 10^9/L), adequate hepatic function (total bilirubin ≤ 1.5×upper normal limit, ASAT and ALAT ≤ 3.0×upper normal limit, alkaline phosphatase ≤ 2.5×upper normal limit, total bilirubin 1.5–2.5×upper normal limit and ASAT or ALAT 3–5×upper normal limit in case of liver metastases).

Exclusion criteria were prior treatment with chemotherapy and the presence of other malignancies (previous or present), except adequately treated in situ carcinoma of the cervix or basal cell carcinoma of the skin and a previous malignancy more than 5 years ago without evidence of recurrence (except for malignant melanoma, hypernephroma, or breast cancer).

3. Treatment

Gemcitabine 1250 mg/m^2 was administered intravenously on days 1 and 8 of courses 1 and 2 as a 30-minute infusion. Paclitaxel 150 mg/m^2 was administered intravenously on days 1 and 8 of courses 3 and 4 as a 3-hour infusion. One course was defined as two weekly doses of chemotherapy followed by one week of rest and one cycle as 2 courses of gemcitabine followed by 2 courses of paclitaxel (Figure 1). At least 1 cycle was administered unless patient refusal or excessive toxicity precluded further therapy. If there was no PD after 1 cycle the same treatment schedule could be repeated up to a maximum of 2 cycles. If PD was observed at the end of the first or second cycle, further treatment was according to local policy.

4. Efficacy and Tolerability Assessments

Study assessments included physical examination, complete blood count, electrocardiogram, tumor measurements (chest X-ray, and chest-upper abdomen computed tomography scan), within 4 weeks before start of the treatment. Routine blood test for blood chemistry and haematological toxicity were performed before each chemotherapy administration. Response evaluation by CT took place after every 2 courses by RECIST criteria [8]. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria version 3 (NCI-CTC) and was assessed every 3 weeks by physical examination, direct questioning, and haematological and biochemical parameters.

5. Statistical Considerations

It was hypothesized that if the sequential regimen had an efficacy lower than 25%, it was unlikely to be of interest and would not result in further investigation. According to Fleming’s single stage procedure P0 was set at 0.20. The response percentage that would certainly warrant further investigation (P1) was set at 0.40. With a power of 0.93 and an α of 0.06 this implies that 35 patients had to be enrolled. For the power calculation the best response during the first cycle has been used. P-values < .05 were considered significant.

6. Results

Twenty-one patients have been enrolled in this trial over a 3-year period due to competing trials in the participating centres. Median age was 56 years (range 38–80 years), 62% (13/21) was male, 38% (8/21) female, 15% (2/21) had stage IIIB, 90% (19/21) stage IV, 15% (2/21) ECOG performance status 0, 85% (18/21) ECOG 1. Ten (47.5%) patients had an adenocarcinoma, 3 (14.5%) squamous cell carcinoma, and 8 (38%) had large cell carcinoma.

One non-evaluable patient died one week after the first gemcitabine dose administration due to a cerebral vascular accident. At that time the platelet count was normal. Of the 20 evaluable patients 20% (4/20) achieved a partial response (PR), 30% (6/20) stable disease (SD), and
| Study          | Phase | N  | Regimen                                      | RR (%) | PD(%) | MS (m) | 1year OS (%) | PFS (m) | Major grade 3-4 toxicity(%) |
|---------------|-------|----|----------------------------------------------|--------|-------|--------|--------------|--------|----------------------------|
| **Doublet → Doublet** |       |    |                                              |        |       |        |              |        |                            |
| Gebbia (9)    | III   | 400| G + IFO (2) → CDDP + VNR (2) versus          | 19     | 59    | NR     | NR           | 3.1^a  | Neutropenia 57/67/26/21    |
|               |       |    | CDDP + VNR (2) → G + IFO (2) versus          | 32     | 33    | NR     | NR           | 5      | Thrombo 32/35/17/10/41     |
|               |       |    | CDDP + VNR (up to 6 cycles) versus           | 44^a   | 25    | 9      | 24           | 4.1    | Vomiting 13/15/21/23       |
|               |       |    | CDDP + G (up to 6 cycles)                    | 34     | 37    | 8.2    | 20           | 4      | Asthenia 29/35/35/35/50    |
| **Doublet → SA** |       |    |                                              |        |       |        |              |        |                            |
| Edelman (10)  | III   | 204| CBDCA + G (3) → PTX (3) versus               | 21     | 29    | 9      | 34           | 4      | Neutropenia 47^a/70        |
|               |       |    | CDDP + VNR (3) → DOC (3)                     | 28     | 22    | 9      | 36           | 4      | Anemia 19/14               |
|               |       |    |                                              |        |       |        |              |        | Thrombocytopenia 37/2^a    |
|               |       |    |                                              |        |       |        |              |        | Fatigue 7^a/18             |
|               |       |    |                                              |        |       |        |              |        | Emesis 5^a/24              |
|               |       |    |                                              |        |       |        |              |        | Toxic deaths 3/3           |
| Clark (11)    | II    | 18 | CDDP (2) + VNR (2) → DOC (4)                 | 31     | 44    | 9.5    | 44           | NR     | Neutropenia 41             |
|               |       |    |                                              |        |       |        |              |        | Toxic deaths 1             |
| Grossi (12)   | II    | 51 | CDDP + PTX (2) → VNR (2) → G (2)            | 43     | 25    | 14     | 53           | 6.8    | Neutropenia 54/30^a        |
|               |       |    |                                              |        |       |        |              |        | Neupathia 21/2^a           |
| Kubota (13)   | III   | 401| CBDCA + PTX (up to 6)                       | 36^a   | 10    | 13.8   | 55.5         | 6      | Neutropenia 20             |
|               |       |    | VNR + G (3) → DOC (3)                       | 23     | 16    | 13.1   | 55.6         | 5.9    | Neuropathy 12              |
|               |       |    |                                              |        |       |        |              |        | Emesis 10                  |
|               |       |    |                                              |        |       |        |              |        | Neutropenia (gr 4) 71      |
|               |       |    |                                              |        |       |        |              |        | Neupathia 14               |
|               |       |    |                                              |        |       |        |              |        | Neuropathy 24              |
| **SA → doublet or triplet** |       |    |                                              |        |       |        |              |        |                            |
| Feliu (14)    | II    | 52 | PTX (6) → CDDP + GEM + VNR (up to 6)         | 56     | 31    | NR     | 56           | 9      | Neutropenia 20             |
|               |       |    |                                              |        |       |        |              |        | Neuropathy 12              |
|               |       |    |                                              |        |       |        |              |        | Emesis 10                  |
|               |       |    |                                              |        |       |        |              |        | Neutropenia (gr 4) 71      |
|               |       |    |                                              |        |       |        |              |        | Neuropathia 14             |
| Rixe (15)     | II    | 32 | DOC (4) → CDDP + VDS (4)                    | 17     | 27    | 11     | 47           | 4.4    | Neutropenia 4              |
|               |       |    |                                              |        |       |        |              |        | Neurology 9                |
| **SA → SA**   |       |    |                                              |        |       |        |              |        |                            |
| Present study | II    | 21 | G → PTX                                     | 20%    | 50    | 8      | 33           | 3      | Neutropenia 36/27          |
|               |       |    |                                              |        |       |        |              |        | Infection 17/13            |
| Manegold (16) | II-III| 338| G + DOC (6) versus                          | 33^a   | NR    | 7.3    | 27           | 6.3^a  | Neutropenia 36/27          |
|               |       |    |                                              |        |       |        |              |        | Infection 17/13            |
|               |       |    | G (3) → DOC (3)                             | 22     | NR    | 7.4    | 25           | 4.9    | Dyspnce 21/20              |
|               |       |    |                                              |        |       |        |              |        | Asthenia 12/11             |
| Martoni (17)  | II    | 52 | G (3) → VNR (until PD)                     | 23     | 23    | 10     | 42           | 6      | Neutropenia 22^c           |
|               |       |    |                                              |        |       |        |              |        | Constipation 3^e           |
| Poon (18)     | II    | 23 | G (3) → CDDP (4)                            | 21     | 52    | 14.6   | 63           | 3.3    | Neutropenia 13             |
|               |       |    |                                              |        |       |        |              |        | Anemia 13                  |

Table 1: Overview of the sequential studies reported in the literature.
50% (10/20) progressive disease (PD). Five patients (25%) progressed after 2 courses of gemcitabine, all of them had an adenocarcinoma. Median time to progression (TTP) was 12 weeks (range 6–52 weeks), the median overall survival (OS) 8 months (range 1–27 months), and the 1-year survival rate 33%. Toxicity was mild; only one patient developed grade 3 hematological toxicity, in two others there was grade 3 peripheral neuropathy occurring at the second cycle. There were no treatment-related deaths. No dose reductions were needed.

7. Discussion

In this non-randomised phase II study, the sequential administration of single agent gemcitabine followed by paclitaxel in the first line treatment of advanced NSCLC had a favourable toxicity profile, a median TTP, and OS comparable with the first line treatment of advanced NSCLC had a favourable toxicity profile, a median TTP, and OS comparable with other sequential trials reported in the literature (Table 1) [9–20].

When we designed our study (2002–2003) Vansteenkiste et al. reported that treatment of patients with symptomatic advanced NSCLC with single agent gemcitabine resulted in a superior clinical-benefit response rate compared to cisplatin-based combination chemotherapy. Gemcitabine was equally effective in controlling “disease-specific” symptoms, but superior in controlling “constitutional” symptoms [21]. Therefore, single agent gemcitabine in first line treatment of stage IIIb/IV NSCLC was at that time a valid therapeutic choice and we decided to investigate the sequential administration of two single agent non-cross resistant chemotherapeutic drugs, gemcitabine, and paclitaxel. In the present study, paclitaxel was selected as sequential agent because taxanes do not require the presence of an intact p53 pathway for apoptosis induction in contrast to DNA-damaging agents like gemcitabine [22]. The dose of paclitaxel of 150 mg/m² was based on the results of phases I and II trials [23–25]. Akerley et al. reported on a phase I trial of weekly paclitaxel administered over 3 hours for 6 consecutive weeks followed by 2 weeks of rest. From this study the recommended phase II dose was 175 mg/m²/week [23]. In the subsequent phase II trial this dose-dense regimen led to a high proportion of grade 3-4 neutropenia and grade 2-3 peripheral neuropathy (32%) [24]. Therefore, in the CALBG study 9713, weekly paclitaxel at a reduced dose of 150 mg/m²/week for 6 consecutive weeks was used followed by 2 weeks of rest. They demonstrated that this dose-dense regimen could be administered safely [25].

Because 50% of the participants in our trial had disease progression and because disease progression occurred already after 2 courses of single agent gemcitabine, we decide to close our study prematurely. At that time, it had also become evident from the literature that single agent gemcitabine in first line treatment of stage IIIb/IV NSCLC was inferior compared to platinum-based doublets [26, 27].

Even though our study has been closed prematurely, our data add to our current understanding on the treatment of NSCLC because they contribute to the concept of maintenance therapy with non-cross resistant drugs. In a recent randomized phase III trial of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care, PFS was 4 months in the pemetrexed arm versus 2 months in the placebo arm with an hazard ratio (HR) of 0.6 (P < .00001) and the OS was 13.4 months versus 10.6 months, respectively (HR 0.79, P = .012) [28]. The phase III trial of immediate versus delayed docetaxel after first line chemotherapy in advanced NSCLC showed also a superior progression free survival (statistically significant) and greater median overall survival (not statistically significant) for the arm with immediate docetaxel [29]. These trials support the rationale of using a non-cross resistant third generation agents before disease progression has occurred. We also believe that a single agent nonplatinum approach could be of value in ERCC1 positive patients, especially in the perspective of individualized treatment.

Table 1: Continued.

| Study | Phase | N = | Regimen | RR (%) | PD (%) | MS (m) | 1-year OS (%) | PFS (m) | Major grade 3-4 toxicity (%) |
|-------|-------|-----|---------|--------|--------|--------|--------------|--------|-----------------------------|
| Hirsch (19) | II | 42 | VNR (2) → G | 38 | 36 | 8 | 29 | 3.5 | No grade 3-4 tox. |
| Tibaldi (20) | II | 56 | G (3) → DOC (3) | 16 | 43 | 8 | 34 | 4.8 | Neutropenia 5.4 Thrombopenia 3.6 Mucositis 3.6 Diarrhea 3.6 Asthenia 9 |

(a) statistically significant.
(b) difference in thrombocytopenia incidence between CT arms was statistically significant (P = .0001).
(c) asthenia more frequent in the GC arm than VC arm (50% versus 35%, P = .015).
(d) toxicity evaluated per cycle.
(e) worst toxicity per step.

G: gemcitabine, IFO: ifosfamide; CDDP: cisplatin; VNR: vinorelbine; CBDCA: carboplatin; PTX: paclitaxel; DOC: docetaxel; RR: response rate; MS: median survival; MPFS: median progression-free survival; NR: not reported; OS: overall survival; PD: progressive disease; SA: single agent

NR: not reported.
Patients with completely resected NSCLC and ERCC1-negative tumors appeared to benefit from adjuvant cisplatin-based chemotherapy, whereas patients with ERCC1-positive tumors did not [30]. A prospective trial of 366 patients, in which patients with low ERCC1 were selected for platinum-based therapy (docetaxel, cisplatin), while those with high ERCC1 expression were directed to alternate non-platinum therapy (docetaxel, gemcitabine), demonstrated a significantly higher overall response rate in the genotypic arm compared to the non-selected control arm [31]. The response rate in the low ERCC1 group receiving platinum chemotherapy was 53%, but the RR in the high ERCC1 non-platinum arm was 47%, compared to 39% for the non-selected group receiving platinum therapy. A prospective phase II feasibility trial in which patient’s therapy was selected based on ERCC1 expression showed that the low ERCC1 group treated with gemcitabine/carboplatin and the high ERCC1 group treated with gemcitabine/docetaxel had a similar median survival of 13 months and response rates of 44% [32].

Our data also confirm that gemcitabine is less active in adenocarcinoma’s than that in squamous cell carcinoma’s [1] because all patients in our trial who progressed after 2 courses of gemcitabine had an adenocarcinoma.

In conclusion, although this non-randomised phase II study failed to meet the primary efficacy endpoint, the sequential administration of single agent gemcitabine followed by paclitaxel in first line treatment of advanced NSCLC had a favourable toxicity profile, a median TTP, and OS comparable with other sequential trials reported in the literature and might, therefore, be a treatment option for NSCLC patients with high ERCC1 expression.

References

[1] G. V. Scagliotti, P. Parikh, J. von Pawel, et al., “Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer,” *Journal of Clinical Oncology*, vol. 26, no. 21, pp. 3534–3551, 2008.

[2] M. D. Fisher and A. D’Orazio, “Phase II and III trials: comparison of four chemotherapy regimens in advanced non-small cell lung cancer (ECOG 1594),” *Clinical Lung Cancer*, vol. 2, no. 1, pp. 21–22, 2000.

[3] F. Fossella, J. R. Pereira, J. von Pawel, et al., “Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group,” *Journal of Clinical Oncology*, vol. 21, no. 16, pp. 3016–3024, 2003.

[4] T. Le Chevalier, D. Brisgang, and J.-Y. Douillard, “Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients,” *Journal of Clinical Oncology*, vol. 12, no. 2, pp. 360–367, 1994.

[5] J. H. Schiller, D. Harrington, C. P. Belani, et al., “Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer,” *The New England Journal of Medicine*, vol. 346, no. 2, pp. 92–98, 2002.

[6] R. S. Day, “Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy,” *Cancer Research*, vol. 46, no. 8, pp. 3876–3885, 1986.

[7] L. Norton, “Evolving concepts in the systemic drug therapy of breast cancer,” *Seminars in Oncology*, vol. 24, no. 4, supplement 10, pp. S10–S3, 1997.

[8] P. Therasse, S. G. Arbuck, E. A. Eisenhauer, et al., “New guidelines to evaluate the response to treatment in solid tumors,” *Journal of the National Cancer Institute*, vol. 92, no. 3, pp. 205–216, 2000.

[9] V. Gebbia, D. Galetta, M. Caruso, et al., “Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide + gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale,” *Lung Cancer*, vol. 39, no. 2, pp. 179–189, 2003.

[10] M. J. Edelman, J. I. Clark, K. Chansky, et al., “Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel,” *Clinical Cancer Research*, vol. 10, no. 15, pp. 5022–5026, 2004.

[11] J. I. Clark, K. Kanchilara, R. Qamar, et al., “Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer,” *Lung Cancer*, vol. 34, no. 2, pp. 271–277, 2001.

[12] F. Grossi, O. Belvedere, G. Fasola, et al., “Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an alpe-adria thoracic oncology multidisciplinary group study (ATOM 001),” *Lung Cancer*, vol. 46, no. 1, pp. 99–106, 2004.

[13] K. Kubota, M. Kawahara, M. O. Ogawara, et al., “Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study,” *The Lancet Oncology*, vol. 9, no. 12, pp. 1135–1142, 2008.

[14] J. Feliu, G. Martin, J. Lizon, et al., “Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study,” *Annals of Oncology*, vol. 12, no. 10, pp. 1369–1374, 2001.

[15] O. Rixe, M. Gatinneau, E. Jauffret, et al., “ Sequential administration of docetaxel followed by cisplatin-vindesine: a pilot study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC),” *Bulletin du Cancer*, vol. 92, no. 1, pp. E1–E6, 2005.

[16] C. Manegold, N. Tatcher, C. Kortsik, et al., “Sequencing of single-agent (SA) docetaxel (T) and gemcitabine (G) therapy for patients (pts) with advanced non-small cell lung cancer (NSCLC): results of three consecutive randomized trials,” *Journal of Clinical Oncology*, vol. 24, no. 18s, p. 7035, 2006.

[17] A. A. Martoni, F. di Fabio, B. Melotti, S. Giaquinta, and M. Guaraldi, “Planned sequence of gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel,” *Lung Cancer*, vol. 39, no. 2, pp. 205–216, 2003.

[18] D. Poon, K. F. Foo, L. Chew, S. S. Leong, J. Wee, and E. H. Tan, “Phase II trial of gemcitabine and cisplatin sequentially administered in Asian patients with unresectable or metastatic non-small cell lung cancer,” *Annals of the Academy of Medicine Singapore*, vol. 35, no. 1, pp. 33–37, 2006.
[19] V. Hirsh, J. Latreille, H. Kreisman, et al., “Sequential therapy with Vinorelbine followed by Gemcitabine in patients with metastatic non small cell lung cancer (NSCLC), performance status (PS) 2, or elderly with comorbidities—a multicenter phase II trial,” *Lung Cancer*, vol. 49, no. 1, pp. 117–123, 2005.

[20] C. Tibaldi, E. Vasilic, A. Antonuzzo, et al., “First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study,” *British Journal of Cancer*, vol. 98, no. 3, pp. 558–563, 2008.

[21] J. Vansteenkiste, J. Vandebroek, C. Dooms, et al., “Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine,” *Lung Cancer*, vol. 40, no. 2, pp. 191–199, 2003.

[22] S. W. Lowe, H. E. Ruley, T. Jacks, and D. E. Housman, “P53-dependent apoptosis modulates the cytotoxicity of anticancer agents,” *Cell*, vol. 74, no. 6, pp. 957–967, 1993.

[23] W. Akerley, M. Glantz, H. Choy, et al., “Phase I trial of weekly paclitaxel in advanced NSCLC,” *Journal of Clinical Oncology*, vol. 16, no. 1, pp. 153–158, 1998.

[24] W. Akerley, “Paclitaxel in advanced NSCLC,” *Chest*, vol. 117, pp. 1525–1555, 2000.

[25] W. Akerley, J. Herndon, and M. J. Egorin, “CALGB 9731: phase II trial of weekly paclitaxel for advanced NSCLC,” *Proceedings of the American Society for Clinical Oncology*, vol. 18, p. 462a, 1999.

[26] G. D’Addario, M. Pintilie, N. B. Leighl, R. Feld, T. Cerny, and F. A. Shepherd, “Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature,” *Journal of Clinical Oncology*, vol. 23, no. 13, pp. 2926–2936, 2005.

[27] C. Sederholm, G. Hillerdal, K. Lamberg, et al., “Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group,” *Journal of Clinical Oncology*, vol. 23, no. 33, pp. 8380–8388, 2005.

[28] C. P. Belani, T. Brodowicz, T. Ciuleanu, et al., “Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized phase III study in advanced non-small cell lung cancer (NSCLC),” *Journal of Clinical Oncology*, vol. 27, p. 18s, 2009.

[29] P. M. Fidias, S. R. Dakhil, A. P. Lyss, et al., “Phase III study of immediate compared with delayed docetaxel after frontline therapy with gemcitabine plus carboplatin in advanced NSCLC,” *Journal of Clinical Oncology*, vol. 27, no. 4, pp. 591–598, 2009.

[30] K. A. Olaussen, A. Dunant, P. Fouret, et al., “DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy,” *The New England Journal of Medicine*, vol. 355, no. 10, pp. 983–991, 2006.

[31] M. Cobo, D. Isla, B. Masuti, et al., “Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer,” *Journal of Clinical Oncology*, vol. 25, no. 19, pp. 2747–2754, 2007.

[32] G. Simon, A. Sharma, X. Li, et al., “Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced NSCLC,” *Journal of Clinical Oncology*, vol. 25, no. 19, pp. 2741–2746, 2007.